Company Information
USD
28.21
- (0.5%)
NASDAQ:RPRX, ROYALTY PHARMA PLC
Industry: Biotechnology
End of Day: 15 May 2024 GMT-4
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Address
110 East 59th Street
Classification
Sector
Healthcare
Industry Group
Biotechnology
Industry
Biotechnology
Key Executives
Mr. David C. Hodgson
Director
Mr. Henry A. Fernandez
Director
Mr. Gregory Norden
Director
Dr. Ted W. Love, M.D.
Director
Mr. Rory B. Riggs
Director
Dr. Errol B. De Souza,PhD
Director
Dr. Bonnie L. Bassler, PhD
Director
Mr. Pablo Legorreta
CEO/Chairman of the Board/Director
Ms. Catherine M. Engelbert
Director
Mr. Terrance Coyne
CFO/Chief Accounting Officer/Executive VP
Mr. M. Germano Giuliani
Director
Mr. Christopher Hite
Executive VP/Vice Chairman
Mr. George Lloyd
Executive VP, Divisional/General Counsel
Dr. Marshall Urist, M.D.
Executive VP, Divisional
Ownership
Institution Holdings
Morgan Stanley - Brokerage Accounts
46,354,266 (10.377%)
FMR LLC
44,110,365 (9.875%)
Morgan Stanley
43,775,398 (9.800%)
Vanguard Group Inc
37,997,522 (8.506%)
FMR Inc
31,583,929 (7.071%)
Fidelity Management & Research Company LLC
25,283,234 (5.660%)
BlackRock Inc
21,459,462 (4.804%)
Baillie Gifford & Co Limited.
17,590,450 (3.938%)
Morgan Stanley Investment Management Ltd
13,575,943 (3.039%)
Vanguard Investments Australia Ltd
12,144,214 (2.719%)
Funds Holdings
Vanguard Total Stock Market Index Fund
11,930,787 (2.671%)
Vanguard US Total Market Shares ETF
11,930,787 (2.671%)
Vanguard Mid-Cap Index Fund
8,469,967 (1.896%)
Morgan Stanley Growth SMA
8,224,744 (1.841%)
Morgan Stanley - Growth
8,224,744 (1.841%)
Morgan Stanley Inst Growth Port
8,224,744 (1.841%)
Fidelity Contrafund
6,635,154 (1.485%)
Vanguard Institutional Extnd Mkt Idx Tr
5,651,488 (1.265%)
MS INVF US Growth Fund
5,095,974 (1.141%)
Vanguard Value Index Fund
3,151,075 (0.705%)
Make Smart Investment Choices
GoodWhale Pte. Ltd.
1557 Keppel Road, #01-01
Singapore 089066
Singapore 089066
